The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people
hospitalized with severe COVID-19 illness has engendered considerable interest in the …

Background. Although vaccine rollout for COVID‐19 has been effective in some countries,
there is still an urgent need to reduce disease transmission and severity. We recently carried …

In the initial process of coronavirus disease 2019 (COVID-19), severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infects respiratory epithelial cells and then transfers …

Background: Lipid metabolism plays an important role in viral infections. We aimed to
assess the causal effect of lipid-lowering drugs (HMGCR inhibitiors, PCSK9 inhibitiors, and …

Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …

Background Cardiovascular disease (CVD), one of the most common comorbidities of
coronavirus disease 2019 (COVID-19), has been suspected to be associated with adverse …

Results The final selected studies (n= 24 studies; 32,715 patients) showed significant
reductions in ICU admission (OR= 0.78, 95% CI: 0.58–1.06; n= 10; I 2= 58.5%) and death …

Abstract Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation,
endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be …

Background Statins have anti-inflammatory and immunomodulatory effects that may reduce
the severity of coronavirus disease 2019 (COVID-19), in which organ dysfunction is …

Objectives There is conflicting evidence about the efficacy of statin use in regard to clinical
outcomes in patients with coronavirus disease 2019 (COVID-19). A systematic review and …